Showing 1 - 12 results of 12 for search 'Non-response', query time: 0.06s Refine Results
  1. 1
  2. 2
  3. 3

    Can patient-reported profiles avoid unnecessary referral to a spine surgeon? An observational study to further develop the Nijmegen Decision Tool for Chronic Low Back Pain. by Miranda L van Hooff, Johanna M van Dongen, Veerle M Coupé, Maarten Spruit, Raymond W J G Ostelo, Marinus de Kleuver

    Published 2018-01-01
    “…The overall performance was acceptable (c-index; 0.72-0.83), the model predicting non-response to surgery performed best (R2 = 39%; c-index = 0.83).…”
    Get full text
    Article
  4. 4
  5. 5

    Pharmacogenomic insights into amlodipine response: the role of CACNA1D, CACNA1C, and TRIB3 variants in hypertensive patients. by Wahby M Babaresh, Zakiullah, Sohaib Ahmad Sohail, Alija Baig, Malik Faisal, Aiman Begum, Haseenullah Shah, Zia Ul Hassan, Kiran Ijaz, Syed Muhammad Mukarram Shah, Aftab Ullah

    Published 2025-01-01
    “…The CACNA1D rs3774426 TT genotype was significantly associated with non-response in 35 patients, showing higher SBP than the CC genotype (n = 69). …”
    Get full text
    Article
  6. 6

    The pandemic of online research in times of COVID-19 by Edwin Wouters, Jeroen De Man, Linda Campbell, Hanani Tabana

    Published 2021-02-01
    “…Online research is prone to various forms of selection bias, including self-selection bias, non-response bias or only reaching specific subgroups. …”
    Get full text
    Article
  7. 7

    Influencing factors of early objective response of unresectable hepatitis B virus⁃related liver cancer with triple therapy by YU Jin*,LI Xiaogang

    Published 2025-08-01
    “…Among them,50 patients with early objective response after triple therapy for unresectable HBV⁃related HCC were divided into the response group,and 37 patients without objective response were divided into the non⁃response group. Logistic regression analysis showed that extrahepatic metastasis(OR=0.264,95%CI:0.076-0.913),alpha⁃fetoprotein(AFP)>400 ng/mL(OR=0.330, 95%CI:0.118- 0.919),and HBV⁃DNA>1 000 IU/mL(OR=0.305,95%CI:0.103- 0.899)were independent risk factors for early objective response in patients with unresectable HBV ⁃ related HCC after triple therapy(P<0.05).Conclusion Extrahepatic metastasis,AFP and HBV ⁃ DNA are independent factors of early objective response in patients with unresectable HBV⁃related liver cancer after triple therapy. …”
    Get full text
    Article
  8. 8

    Reporting and handling of missing data in published studies of co-morbid hypertension and diabetes among people living with HIV/AIDS: a systematic review by Peter Vanes Ebasone, Nasheeta Peer, Anastase Dzudie, Johney Melpsa, Merveille Foaleng, Andre Pascal Kengne

    Published 2025-07-01
    “…Only 19 of these studies (37.7%) cited reasons for missingness, predominantly attributed to lack of documentation and non-response. Out of the 24 (45.5%) studies that detailed how they handled missing data, the majority (16 studies; 30.2%) used complete case analysis. …”
    Get full text
    Article
  9. 9

    Mycophenolate mofetil versus azathioprine as a first-line treatment for autoimmune hepatitis: a comparative systematic review and meta-analysis by Amani M. Ali, Mohamed E. Abdelrahim, Aya M. AbdelMagid

    Published 2025-08-01
    “…Efficacy was assessed based on complete biochemical remission (CBR), non-response, and relapse rates. Safety was evaluated on the basis of the incidence of serious adverse effects that led to treatment discontinuation. …”
    Get full text
    Article
  10. 10

    BAFF/APRIL expression-guided telitacicept therapy demonstrates superior efficacy in systemic lupus erythematosus patients: a real-world comparative study by Li Huang, Yingzi Huang, Jiamin Zeng, Huhai Zhang, Liping Chen, Yi Li, Hongwen Zhao, Xiaopeng Tang

    Published 2025-08-01
    “…Clinical responses, laboratory parameters, and steroid-sparing effects were assessed at 3 and 6 months.ResultsDespite having significantly higher baseline disease activity (SLEDAI 18.79 ± 9.34 vs. 8.86 ± 4.3) and more severe proliferative lupus nephritis (Class IV/IV + V in 78.6% vs. 52.8%), the BAFF/APRIL-guided telitacicept group achieved higher complete response rates (57.1% vs. 48.6%) and lower non-response rates (7.1% vs. 23.6%) compared to the conventional belimumab group. …”
    Get full text
    Article
  11. 11

    Longitudinal CE-MRI-based Siamese network with machine learning to predict tumor response in HCC after DEB-TACE by Nan Wei, René Michael Mathy, De-Hua Chang, Philipp Mayer, Jakob Liermann, Christoph Springfeld, Michael T Dill, Thomas Longerich, Georg Lurje, Hans-Ulrich Kauczor, Mark O. Wielpütz, Osman Öcal

    Published 2025-08-01
    “…The patients were categorized into two groups: the objective response group (n = 123, 60.9%; complete response = 35, 28.5%; partial response = 88, 71.5%) and the non-response group (n = 79, 39.1%; stable disease = 62, 78.5%; progressive disease = 17, 21.5%). …”
    Get full text
    Article
  12. 12

    Sleep quality and the biological stress system during an internet-based intervention for major depressive disorder by Sebastian Laufer, Johannes Bohn, Sinha Engel, Hannah Klusmann, Nadine Skoluda, Urs M. Nater, Christine Knaevelsrud, Sarah Schumacher

    Published 2025-11-01
    “…We hypothesized that: 1) short-term and long-term sleep quality would improve during the intervention, 2a) across assessment time points, poor sleep quality would be associated with higher cortisol and alpha-amylase concentrations, and 2b) pre-to-post intervention improvements in sleep quality (treatment response) would be associated with pre-to-post decreases in both biological markers, compared to non-response. Methods: We analyzed forty-one participants (age: 35 ± 12y; females: 82.6 %) suffering from mild to moderate MDD. …”
    Get full text
    Article